Hanover Insurance Group (THG) EVP receives 11.844 RSUs via dividend equivalents
Rhea-AI Filing Summary
Hanover Insurance Group, Inc. reported a routine equity award transaction for an executive officer. On 12/26/2025, the officer, who serves as Executive Vice President, received 11.844 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 under the company’s 2022 Long-Term Incentive Plan.
The RSUs were granted as dividend equivalent rights tied to RSUs previously awarded under the same plan. These additional RSUs will vest on the third anniversary of the grant date of the original underlying RSUs. Following this transaction, the officer beneficially owns 3,523.34 shares of Hanover common stock in direct form.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 11.844 | $0.00 | -- |
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Hanover Insurance Group (THG) report in this Form 4?
The filing reports that an executive officer received 11.844 restricted stock units (RSUs) of Hanover Insurance Group, Inc. common stock on 12/26/2025 at a price of $0 per share.
What is the source of the new RSUs reported for Hanover Insurance Group (THG)?
The 11.844 RSUs were granted under the company’s 2022 Long-Term Incentive Plan as dividend equivalent rights related to RSUs previously granted under the same plan.
When will the new Hanover Insurance Group (THG) RSUs vest?
The filing states that these RSUs vest on the third anniversary of the date of grant of the original underlying RSUs to which the dividend equivalents relate.
What is the reporting person’s role at Hanover Insurance Group (THG)?
The reporting person is identified as an Officer of Hanover Insurance Group, Inc., holding the title of Executive Vice President.
Did the reporting officer pay anything for the Hanover Insurance Group (THG) RSUs?
No cash was paid for the RSUs in this transaction; the 11.844 RSUs were granted at a reported price of $0 as dividend equivalent rights.